Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

Y0000297

Mesalazine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5-Aminosalicylic acid, 5-AS, 5-Amino-2-hydroxybenzoic acid, Mesalamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
H2NC6H3-2-(OH)CO2H
CAS Number:
89-57-6
Molecular Weight:
153.14
Beilstein:
2090421
MDL number:
MFCD00007877
UNSPSC Code:
41116107
PubChem Substance ID:
329830901
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

mesalamine, mesalazine

manufacturer/tradename

EDQM

mp

275-280 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI key

KBOPZPXVLCULAV-UHFFFAOYSA-N

Gene Information

human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

5-Aminosalicylic acid is a peroxidase substrate suitable for use in ELISA procedures. This substrate produces a soluble end product that is brown in color and can be read spectrophotometrically at 450 nm. The reaction may be stopped with 3 N NaOH and read at 550 nm.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1148

4-Aminophenol (Acetaminophen Related Compound K) (Paracetamol Impurity K), Pharmaceutical Secondary Standard; Certified Reference Material

1021204

4-Aminophenol, United States Pharmacopeia (USP) Reference Standard

1633506

Sulfanilic acid, United States Pharmacopeia (USP) Reference Standard

PHR1225

3-Aminophenol, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001574

Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001563

Mesalazine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001569

Mesalazine impurity C, European Pharmacopoeia (EP) Reference Standard

PHR1419

Sulfanilic Acid, Pharmaceutical Secondary Standard; Certified Reference Material

1392705

Mesalamine, United States Pharmacopeia (USP) Reference Standard

1026004

m-Aminophenol, United States Pharmacopeia (USP) Reference Standard

PHR1739

Mesalazine Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1741

2-Chloro-5-nitrobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

BP1075

Mesalazine, British Pharmacopoeia (BP) Reference Standard

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315 - H317 - H319 - H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

No data available

Flash Point(C)

No data available

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jeffrey B Raskin et al.
Gastroenterology, 147(4), 793-802 (2014-07-20)
No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of
David T Rubin et al.
Inflammatory bowel diseases, 14(2), 265-274 (2007-10-13)
A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5-aminosalicylic acid. Specific topics
Max Karner et al.
The American journal of gastroenterology, 109(7), 1041-1051 (2014-05-07)
Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modified release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in a
A M Schoepfer et al.
Alimentary pharmacology & therapeutics, 40(8), 930-937 (2014-08-26)
There is uncertain evidence of effectiveness of 5-aminosalicylates (5-ASA) to induce and maintain response and remission of active Crohn's disease (CD), and weak evidence to support their use in post-operative CD. To assess the frequency and determinants of 5-ASA use
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service